ALASTAIR Cook was told he had terminal liver cancer in July 2024. His devastating diagnosis was caused by a ‘silent killer’ virus he got after a traumatic car crash almost four decades ...

Treatment may include a combination of medications, lifestyle changes, and, in severe cases, surgical interventions such as liver transplantation. There are over 100 types of liver disease, including ...

When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's ...

William Blair has the equivalent of a buy rating on the stock, as do all 13 analysts offering coverage of the stock on FactSet. The bank is one of many expecting Viking to be a takeover target, given ...

The GLP-1 receptor agonist improved both histology and fibrosis in patients, with additional improvements in their liver ...

Semaglutide (Wegovy) improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) and led ...

Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH ...

Patients in the treatment arms received 1 mg, 2.5 mg, 5 mg or 10 mg doses. After 52 weeks of treatment, patients taking the ...

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

A study led by scientists at Massachusetts General Hospital has found that growth hormone could help improve liver health in ...

The response rate in this study -- the proportion of patients experiencing reduction in liver fat ≥30% -- ranged from 64% to ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...